MBX Biosciences Inc

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences:

MBX Biosciences to Participate in Upcoming November Investor Conferences

CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company's potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism (HP) were featured in a poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting held in Toronto, ON, Canada September 27-30, 2024.

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

Bicara Therapeutics Inc

Zenas Biopharma Inc

24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.

Last Week's 3 Biotech IPOs Prompt Huge Insider Buying

CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to MBX Biosciences from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses.

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Future Vision II Acquisition Corp

Galaxy Payroll Group Ltd

Trident Digital Tech Holdings Ltd

XCHG Ltd

Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand courier service provider BingEx also filed to raise $100 million. No IPOs are currently scheduled to list in the week ahead, as activity remains somewhat muted in the run-up to the 2024 presidential election.

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Shares of MBX Biosciences , which is developing therapies that target endocrine and metabolic disorders, including diabetes and obesity, rose nearly 44% in their Nasdaq debut on Friday, underscoring investors' focus on weight-loss drugs.

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial public offering.

MBX Biosciences raises $163.2 mln in US IPO

CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its initial public offering of 10,200,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $163.2 million. All of the shares are being offered by MBX Biosciences. In addition, MBX Biosciences has granted the underwriters a 30-day option to buy an additional 1,530,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

MBX Biosciences Announces Pricing of Initial Public Offering

News for MBX Biosciences Inc Stock (MBX)